Lao Juan, Madani Julia, Puértolas Teresa, Alvarez María, Hernández Alba, Pazo-Cid Roberto, Artal Angel, Antón Torres Antonio
Medical Oncology Department, Miguel Servet University Hospital, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain ; Aragón Institute of Health Sciences, Avda. San Juan Bosco, 13, planta 1, 50009 Zaragoza, Spain.
J Drug Deliv. 2013;2013:456409. doi: 10.1155/2013/456409. Epub 2013 Mar 26.
Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer agents. Liposome drug delivery systems are able to modify the pharmacokinetics and biodistribution of cytostatic agents, increasing the concentration of the drug released to neoplastic tissue and reducing the exposure of normal tissue. Anthracyclines are a key drug in the treatment of both metastatic and early breast cancer, but one of their major limitations is cardiotoxicity. One of the strategies designed to minimize this side effect is liposome encapsulation. Liposomal anthracyclines have achieved highly efficient drug encapsulation and they have proven to be effective and with reduced cardiotoxicity, as a single agent or in combination with other drugs for the treatment of either anthracyclines-treated or naïve metastatic breast cancer patients. Of particular interest is the use of the combination of liposomal anthracyclines and trastuzumab in patients with HER2-overexpressing breast cancer. In this paper, we discuss the different studies on liposomal doxorubicin in metastatic and early breast cancer therapy.
药物递送系统能够提高抗癌药物的疗效和/或降低其毒性。脂质体药物递送系统能够改变细胞抑制剂的药代动力学和生物分布，增加释放到肿瘤组织中的药物浓度，并减少正常组织的暴露。蒽环类药物是治疗转移性和早期乳腺癌的关键药物，但其主要局限性之一是心脏毒性。旨在将这种副作用降至最低的策略之一是脂质体包封。脂质体蒽环类药物已实现高效的药物包封，并且已证明作为单一药物或与其他药物联合用于治疗接受过蒽环类药物治疗或未接受过治疗的转移性乳腺癌患者时，它们有效且心脏毒性降低。特别值得关注的是脂质体蒽环类药物与曲妥珠单抗联合用于HER2过表达乳腺癌患者的情况。在本文中，我们讨论了关于脂质体阿霉素在转移性和早期乳腺癌治疗中的不同研究。
